Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
Follow HOWL
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
17.90 | 92.57 | 157.53 | 129.32 | 134.34 | 111.00 | 57.05 |
Receivables |
— | — | — | 6.93 | 1.35 | — | — |
Total current assets |
18.06 | 92.91 | 161.07 | 140.20 | 138.37 | 113.07 | 58.59 |
Property, Plant, Equpment (Net) |
0.24 | 0.65 | 2.91 | 8.99 | 7.96 | 6.32 | 4.69 |
Long-term assets (Other) |
0.21 | 0.21 | 1.86 | 2.59 | 21.62 | 1.54 | 0.91 |
Total non-current assets |
3.62 | 3.48 | 18.18 | 20.05 | 36.46 | 13.86 | 10.81 |
Total Assets |
21.68 | 96.40 | 179.25 | 160.25 | 174.83 | 126.93 | 69.40 |
Notes Payable |
— | — | — | — | 6.67 | — | 28.24 |
Accounts Payable |
0.63 | 1.02 | 2.04 | 1.22 | 1.34 | 3.04 | 0.75 |
Accrued Expenses |
0.82 | 3.59 | 8.77 | 14.15 | 8.86 | 10.59 | 5.41 |
Current Revenue (Deferred) |
— | — | — | 6.53 | 0.91 | — | — |
Total current liabilities |
2.04 | 5.28 | 11.87 | 23.99 | 19.38 | 15.18 | 36.15 |
Long Term Debt (Total) |
9.84 | 1.86 | 14.59 | 12.60 | 32.66 | 26.10 | — |
Non-current Revenue (Deferred) |
— | — | — | 1.13 | 0.43 | — | — |
Liabilities (Preferred Stock) |
41.37 | 141.08 | — | — | — | — | — |
Non-current Liabilities (Other) |
0.02 | 0.03 | — | 0.19 | — | 2.83 | 0.76 |
Total non-current liabilities |
43.94 | 142.98 | 14.59 | 13.92 | 44.08 | 38.36 | 8.44 |
Total liabilities |
45.98 | 148.26 | 26.46 | 37.91 | 63.46 | 53.54 | 44.59 |
Additional Paid In Capital |
0.10 | 0.00 | 405.68 | 429.04 | 455.44 | 487.97 | 500.21 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Retained Earnings |
(24.41) | (51.86) | (252.89) | (306.70) | (344.07) | (414.59) | (475.41) |
Common Equity (Total) |
(24.30) | (51.86) | 152.79 | 122.34 | 111.37 | 73.39 | 24.81 |
Shareholders Equity (Total) |
(24.30) | (51.86) | 152.79 | 122.34 | 111.37 | 73.39 | 24.81 |
Shareholders Equity and Liabilities (Total) |
21.68 | 96.40 | 179.25 | 160.25 | 174.83 | 126.93 | 69.40 |
Shares (Common) |
27.54 | 1.18 | 27.31 | 31.43 | 39.11 | 44.83 | 48.60 |
Shareholders Equity (Tangible) |
(24.30) | (51.86) | 152.79 | 122.34 | 111.37 | 73.39 | 24.81 |
Net Debt |
(8.05) | (90.71) | (142.94) | (116.71) | (101.69) | (84.90) | (57.05) |
Total Debt |
9.84 | 1.86 | 14.59 | 12.60 | 32.66 | 26.10 | — |